Carregant...
Beyond PD-L1 Markers for Lung Cancer Immunotherapy
Immunotherapy using immune checkpoints inhibitors has become the standard treatment for first and second line therapy in patients with non-small cell lung cancer (NSCLC). However, proper predictive factors allowing precise qualification of NSCLC patients for immunotherapy have not been developed so...
Guardat en:
| Publicat a: | Int J Mol Sci |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6515086/ https://ncbi.nlm.nih.gov/pubmed/31003463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20081915 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|